Arrowhead Pharmaceuticals Inc (ARWR)
Debt-to-equity ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 160,407 | 271,343 | 364,830 | 446,772 | 377,039 | 398,520 | 453,927 | 452,266 | 372,560 | 408,822 | 436,890 | 445,549 | 454,472 | 461,779 | 493,140 | 494,119 | 500,084 | 244,591 | 226,225 | 201,195 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $160,407K
= 0.00
Based on the data provided across the quarterly periods from Q2 2022 to Q1 2024, Arrowhead Pharmaceuticals Inc. consistently maintained a debt-to-equity ratio of 0.00. This indicates that the company had no debt relative to its equity during these periods. A debt-to-equity ratio of 0.00 suggests that Arrowhead relied solely on equity financing to support its operations, which may signify a conservative financial strategy with a low risk of financial distress due to debt obligations. While analyzing a single ratio in isolation may not provide a complete financial picture, the sustained zero debt-to-equity ratio could reflect a strong financial position and sound capital structure management on the part of Arrowhead Pharmaceuticals Inc.
Peer comparison
Dec 31, 2023